However, in contrast to the success obtained with CD19 CAR T cells for B-cell malignancies, the progress in AML has been hindered by several challenges, such as the identification of tumor-specific antigens and disease heterogeneity (34). Here, CD19 is linked to acute myeloid leukemia.